The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
Official Title: MR Techniques in the Evaluation of Hepatocellular Carcinoma: Gadoxetate
Study ID: NCT02578602
Brief Summary: This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer. Diagnostic procedures, such as MRI with gadoxetate disodium, may help find and diagnose liver cancer and find out how far the disease has spread. It is not yet known whether MRI with gadoxetate disodium provides a more precise measurement of liver tumors than standard computed tomography (CT).
Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the precision of gadoxetate (gadoxetate disodium)-enhanced MRI in evaluating lesion size. II. To evaluate if there is a subjective improvement in the delineation of hepatocellular carcinoma (HCC) in the hepatocellular phase of contrast administration. III. To further assess the sensitivity of gadoxetate-enhanced MRI for the detection of HCC. SECONDARY OBJECTIVES: I. To evaluate the reproducibility of various tumor measurement techniques in the evaluation of HCC. II. To further evaluate how administration of gadoxetate affects diffusion weighted imaging. OUTLINE: Patients receive gadoxetate disodium intravenously (IV) and then undergo enhanced liver MRI. After completion of study, patients are followed up at 2, 4, 8, and 12 months.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Name: Gilbert Whang
Affiliation: University of Southern California
Role: PRINCIPAL_INVESTIGATOR